Coverage with evidence development, a provisional reimbursement strategy that provides coverage for promising new technologies under the condition that providers collect clinical data, has been touted as a strategy to boost clinical evidence and curb unnecessary healthcare costs. However, much room for improvement remains, and was outlined in a viewpoint published May 6 in JAMA Internal Medicine.
